Aptose terminates $75M ATM equity distribution agreement with Piper Sandler and Canaccord

Aptose Biosciences Inc.

Terminated Equity Distribution Agreement dated May 5, 2020, effective Nov 18, 2022.
No penalties associated with termination; company no longer intends to use facility.
Prior to termination, only ~$86K in net proceeds raised from the $75M facility.
Placement agents were Piper Sandler & Co. and Canaccord Genuity LLC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aptose Biosciences Inc. terminated Equity Distribution Agreement with Piper Sandler & Co. and Canaccord Genuity LLC valued at up to an aggregate of $75,000,000 (effective 2022-11-18).

Action: termination
Agreement: atm program
Counterparty: Piper Sandler & Co. and Canaccord Genuity LLC
Value: up to an aggregate of $75,000,000
Effective: 2022-11-18

Exact text from the filing

On November 18, 2022, Aptose Biosciences Inc. (the “Company”) delivered written notice to Piper Sandler & Co. and Canaccord Genuity LLC (together, the “Placement Agents”) to terminate that certain Equity Distribution Agreement dated May 5, 2020 by and between the Company and the Placement Agents (the “Equity Distribution Agreement”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.